A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 6, 2013, Pages 646-656

  Jabbour, Elias ^a   Lipton, Jeffrey H ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dasatinib; Imatinib; Nilotinib; Outcomes; Response

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB;

ALOPECIA; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EVENT FREE SURVIVAL; EYELID EDEMA; FATIGUE; FLUID RETENTION; FOLLOW UP; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; PRURITUS; PULMONARY HYPERTENSION; QT PROLONGATION; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

DASATINIB; IMATINIB; NILOTINIB; OUTCOMES; RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RESEARCH DESIGN; THIAZOLES; TREATMENT OUTCOME;

EID: 84887991063     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.05.012     Document Type: Review

References (62)

1. A. Quintás-Cardama, and J. Cortes Molecular biology of bcr-abl1-positive chronic myeloid leukemia Blood 113 2009 1619 1630
2. A. Quintás-Cardama, and J.E. Cortes Chronic myeloid leukemia: diagnosis and treatment Mayo Clin Proc 81 2006 973 988
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia Version 4.2013. Fort Washington, PA: National Comprehensive Cancer Network; 2013. Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed May 1, 2013.
4. Gleevec® (imatinib mesylate) [prescribing information] 2013 Novartis Pharmaceuticals Corporation East Hanover, NJ
5. J.E. Cortes, M. Baccarani, and F. Guilhot Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 28 2010 424 430
6. Tasigna® (nilotinib) [prescribing information] 2013 Novartis Pharmaceuticals Corporation East Hanover, NJ
7. G. Saglio, D.-W. Kim, and S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
8. Sprycel® (dasatinib) [prescribing information] 2013 Bristol-Myers Squibb Company Princeton, NJ
9. H. Kantarjian, N.P. Shah, and A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
10. S.G. O'Brien, F. Guilhot, and R.A. Larson Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 2003 994 1004
11. B.J. Druker, F. Guilhot, and S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
12. J.E. Cortes, D. Jones, and S. O'Brien Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase J Clin Oncol 28 2010 392 397
13. J.E. Cortes, D. Jones, and S. O'Brien Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia J Clin Oncol 28 2010 398 404
14. M. Deininger, S.G. O'Brien, and F. Guilhot International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib Blood 114 2009 abstract 1126
15. T.P. Hughes, J. Kaeda, and S. Branford Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
16. M. Baccarani, B.J. Druker, and J. Cortes-Franco 24 Months update of the TOPS study: a phase III, randomized, open-label study of 400mg/d (SD-IM) versus 800mg/d (HD-IM) of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) Blood 114 2009 abstract 337
17. G. Rosti, F. Castagnetti, and G. Gugliotta Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML WP clinical trial Blood 116 2010 abstract 359
18. H.M. Kantarjian, A. Hochhaus, and G. Saglio Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial Lancet Oncol 12 2011 841 851
19. R.A. Larson, A. Hochhaus, and T.P. Hughes Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up Leukemia 26 2012 2197 2203
20. H. Kantarjian, N.P. Shah, and J.E. Cortes Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 2012 1123 1129
21. A. Hochhaus, S.G. O'Brien, and F. Guilhot Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 23 2009 1054 1061
22. T.P. Hughes, A. Hochhaus, and S. Branford Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Blood 116 2010 3758 3765
23. R. Hehlmann, S. Jung-Munkwitz, and M. Lauseker Randomized comparison of imatinib 800 mg vs. imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: analysis of molecular remission at 12 months; the German CML-Study IV Blood 114 2009 abstract 339
24. R. Hehlmann, M. Lauseker, and S. Jung-Munkwitz Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia J Clin Oncol 29 2011 1634 1642
25. C. Preudhomme, J. Guilhot, and F.E. Nicolini Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia N Engl J Med 363 2010 2511 2521
26. P.D. le Coutre, F.J. Giles, and A. Hochhaus Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results Leukemia 26 2012 1189 1194
27. H. Kantarjian, J. Cortes, and D.-W. Kim Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up Blood 113 2009 6322 6329
28. H.M. Kantarjian, F.J. Giles, and K.N. Bhalla Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results Blood 117 2011 1141 1145
29. G. Saglio, A. Hochhaus, and Y.T. Goh Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study Cancer 116 2010 3852 3861
30. N.P. Shah, D.-W. Kim, and H. Kantarjian Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica 95 2010 232 240
31. T. O'Hare, D.K. Walters, and E.P. Stoffregen In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants Cancer Res 65 2005 4500 4505
32. E. Weisberg, P.W. Manley, and W. Breitenstein Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
33. D.L. White, V.A. Saunders, and P. Dang Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity Blood 110 2007 4064 4072
34. D.L. White, V.A. Saunders, and P. Dang OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 2006 697 704
35. D.K. Hiwase, V. Saunders, and D. Hewett Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications Clin Cancer Res 14 2008 3881 3888
36. H. de Lavallade, J.F. Apperley, and J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
37. H. Kantarjian, S. O'Brien, and J. Shan Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112 2008 837 845
38. D. Marin, D. Milojkovic, and E. Olavarria European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 2008 4437 4444
39. E. Jabbour, H. Kantarjian, and S. O'Brien Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure Blood 117 2011 1822 1827
40. A. Hochhaus, M.C. Müller, and J. Radich Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value Leukemia 23 2009 1628 1633
41. C.S. Tam, H. Kantarjian, and G. Garcia-Manero Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia Blood 112 2008 516 518
42. A. Quintás-Cardama, H.M. Kantarjian, and L. Rajyalakshmi Efficacy of frontline nilotinib therapy in patients (pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP) Blood 118 2011 abstract 454
43. G. Rosti, F. Palandri, and F. Castagnetti Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia Blood 114 2009 4933 4938
44. G. Saglio, P.D. LeCoutre, and R. Pasquini Nilotinib versus imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month (mo) follow-up Blood 118 2011 abstract 452
45. A. Hochhaus, F. Guilhot, and K.H. Al-Ali Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly-diagnosed patients with chronic myeloid leukemia in chronic phase: analysis of ENESTnd 3-year data Haematologica 97(Suppl) 2012 abstract 0584
46. A. Hochhaus, G. Ossenkoppele, and J. Reiffers Results from the ENESTnd extension study: efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP), treated with nilotinib 400 mg twice daily (BID) after suboptimal response (SoR) or treatment failure (TF) to imatinib 400 mg once daily (QD) or nilotinib 300 mg BID Blood 118 2011 abstract 114
47. E. Jabbour, N. Shah, and C. Chuah An exploratory analysis from 3-year DASISION follow-up examining the impact on patient outcomes of early complete cytogenetic response at 3 months and major molecular response at 12 months Haematologica 97(Suppl) 2012 abstract 1106
48. Saglio G, Kantarjian HM, Shah N, et al. Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. Blood 2012; 120: abstract 1675.
49. J.P. Radich, K.J. Kopecky, and F.R. Appelbaum A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemia Blood 120 2012 3898 3905
50. M. Baccarani, M.W. Deininger, and G. Rosti European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Blood 122 2013 872 884
51. H. Kantarjian, S. O'Brien, and E. Jabbour Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia J Clin Oncol 29 2011 3173 3178
52. B. Simonsson, K. Porkka, and J. Richter Second-generation BCR-ABL kinase inhibitors in CML N Engl J Med 363 2010 1673 author reply 1673-5
53. J.E. Signorovitch, E.Q. Wu, and K.A. Betts Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials Curr Med Res Opin 27 2011 1263 1271
54. W. Rasheed, B. Flaim, and J.F. Seymour Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia Leuk Res 33 2009 861 864
55. D. Mattei, M. Feola, and F. Orzan Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient Bone Marrow Transplant 43 2009 967 968
56. D. Dumitrescu, C. Seck, and H. ten Freyhaus Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia Eur Respir J 38 2011 218 220
57. J.K. Hennigs, G. Keller, and H.J. Baumann Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11 2011 30
58. E.M. Orlandi, B. Rocca, and A.S. Pazzano Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia Leuk Res 36 2012 e4 e6
59. L. Philibert, C. Cazorla, and H. Peyrière Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib Fundam Clin Pharmacol 25 Suppl 1 2011 abstract 476
60. D. Montani, E. Bergot, and S. Günther Pulmonary arterial hypertension in patients treated by dasatinib Circulation 125 2012 2128 2137
61. A. Quintás-Cardama, H. Kantarjian, and J. Cortes Nilotinib-associated vascular events Clin Lymphoma Myeloma Leuk 12 2012 337 340
62. M. Schwarz, T.D. Kim, and T. Mirault Elevated risk of peripheral artery occlusive disease (PAOD) in nilotinib treated chronic phase chronic myeloid leukemia (CML) patients assessed by ankle-brachial-index (ABI) and duplex ultrasonography Blood 120 2012 abstract 914